[Addressing the Risk of 12 Million People by 2050] Imagina Launches 'Kenchonavi®' to Expose Risks for Over 30 Diseases, Including MCI; Shedding Light on Preventive Healthcare for a Super-Aging Society
NQ Score
85/100
N1 Content Completeness
9
Key facts
- [Addressing the Risk of 12 Million People by 2050] Imagina Launches 'Kenchonavi®' to Expose Risks for Over 30 Diseases, Including MCI; Shedding Light on Preventive Healthcare for a Super-Aging Society
- On June 11, 2026, Imagina began the full-scale rollout of 'Kenchonavi®', a next-generation intestinal flora analysis service that allows users to easily visualize risks for over 30 diseases at home, including colon cancer, depression, and MCI (Mild Cognitive Impairment). The service utilizes patented technology from Synbiosis Solutions to offer high-precision preventive healthcare solutions.
- Source: PR TIMES
- Date: Fri Jun 12 2026 07:00:01 GMT+0900 (Japan Standard Time)
Direct answer
On June 11, 2026, Imagina began the full-scale rollout of 'Kenchonavi®', a next-generation intestinal flora analysis service that allows users to easily visualize risks for over 30 diseases at home, including colon cancer, depression, and MCI (Mild Cognitive Impairment). The service utilizes patented technology from Synbiosis Solutions to offer high-precision preventive healthcare solutions.
- Citation
- [Addressing the Risk of 12 Million People by 2050] Imagina Launches 'Kenchonavi®' to Expose Risks for Over 30 Diseases, Including MCI; Shedding Light on Preventive Healthcare for a Super-Aging Society (Fri Jun 12 2026 07:00:01 GMT+0900 (Japan Standard Time)), PR TIMES
- Source
- PR TIMES
- Date
- Fri Jun 12 2026 07:00:01 GMT+0900 (Japan Standard Time)
AI Summary (NQ-processed)
On June 11, 2026, Imagina began the full-scale rollout of 'Kenchonavi®', a next-generation intestinal flora analysis service that allows users to easily visualize risks for over 30 diseases at home, including colon cancer, depression, and MCI (Mild Cognitive Impairment). The service utilizes patented technology from Synbiosis Solutions to offer high-precision preventive healthcare solutions.
AI Analysis
Frequently Asked Questions
- Q: 「健腸ナビ®」とはどのようなサービスですか？
- A: 自宅で手軽に大腸がん、うつ病、MCI（軽度認知障害）など30種類以上の疾患リスクを、腸内フローラ検査を通じて可視化・分析するサービスです。
- Q: 他の腸内フローラ検査と何が異なりますか？
- A: 国内唯一のMCIリスク判定機能に加え、世界初の特許技術「共分散構造分析（SEM）」を用い、約2.7万人分のデータベースと照合することで超高精度なリスク予測を実現しています。
- Q: 検査の手順はどのようになっていますか？
- A: 自宅で専用キットを用いて採便し、ポストに投函後、Webアンケートに回答するのみで、約1か月後に精緻なWEBレポートが発行されます。
- Q: なぜ「性差」を考慮しているのですか？
- A: 腸内フローラの構成や疾患の発症プロセスには明確な男女差があるため、男女別の専用判定プログラムにより網羅的な疾患リスク可視化を行っています。
- Q: 検査申し込みはどこからできますか？
- A: 専用窓口（https://kenchonavi-lp.netlify.app/）より24時間受け付けています。